Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23256330 | 0.77 | GRIN2B (0.40) | GRIN2BMEN1KMT2AALDH1A1 | |
| SCHEMBL4136436 | 0.76 | CYP2D6 (0.50) | LMNAOPRL1KMT2ACYP3A4ALDH1A1 | |
| SCHEMBL23203521 | 0.73 | ALDH1A1 (0.39) | LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL2998322 | 0.71 | HSD11B1 (0.31) | GRIN2BALDH1A1 | |
| SCHEMBL28641817 | 0.71 | CTSB (0.42) | MEN1MAPTKMT2ACYP3A4ALDH1A1 | |
| SCHEMBL25286794 | 0.71 | — | — | |
| SCHEMBL4874228 | 0.71 | — | — | |
| SCHEMBL2390990 | 0.70 | CYP3A4 (0.39) | LMNAOPRL1MEN1MAPTKMT2A | |
| SCHEMBL23458987 | 0.69 | ALDH1A1 (0.42) | LMNAMEN1KMT2ACYP3A4ALDH1A1 | |
| SCHEMBL23458984 | 0.69 | ALDH1A1 (0.42) | LMNAMEN1KMT2ACYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184805-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184805-A1 | RENIN INHIBITORS | ACE, REN, ACE2 | LMNA 3624/4885GRIN2B 1490/4885OPRL1 1448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.